title: Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma.
abstract: The advanced stages of cutaneous T cell lymphoma (CTCL) are characterized not only by decreased levels of pro-inflammatory cytokines, resulting in high susceptibility to infections, but also by high constitutive activity of NFκB, which promotes cell survival and resistance to apoptosis. The increased expression of the proto-oncogene Bcl3 belonging to IκB family is associated with the pathogenesis of the different types of human cancer, yet, the function and regulation of Bcl3 in CTCL have not been studied. Here, we show that Bcl3 is highly expressed in CTCL Hut-78 and HH cells. The suppression of Bcl3 levels decreases the expression of the pro-survival genes cIAP1 and cIAP2, reduces cell viability, and increases CTCL apoptosis. Interestingly, Bcl3 suppression concomitantly increases expression and the release of the pro-inflammatory cytokines IL-8 and IL-17 in CTCL cells. Chromatin immunoprecipitation studies show that Bcl3 regulates cIAP1, cIAP2, IL-8 and IL-17 gene expression through direct binding to their promoters. Bcl3 expression is regulated by bortezomib (BZ)-mediated proteasome inhibition, and BZ inhibits Bcl3 recruitment to its target promoters, resulting in decreased expression of cIAP1 and cIAP2, but increased expression of IL-8 and IL-17. The Bcl3 expression is regulated through NFκB subunit exchange on Bcl3 promoter. In untreated cells, the Bcl3 promoter is occupied predominantly by p65/p50 heterodimers, inducing Bcl3 expression; however, in BZ-treated cells, the p65/50 heterodimers are replaced by p52 subunits, resulting in Bcl3 transcriptional repression. These data provide the first insights into the function and regulation of Bcl3 in CTCL, and indicate that Bcl3 has an important pro-survival and immunosuppressive role in these cells.
authors.affiliation: Department of Biological Sciences, St. John's University, New York, NY 11439, USA.
authors.forename: Tzu-Pei
authors.initials: TP
authors.lastname: Chang
authors.affiliation: Department of Biological Sciences, St. John's University, New York, NY 11439, USA. Electronic address: vancuroi@stjohns.edu.
authors.forename: Ivana
authors.initials: I
authors.lastname: Vancurova
keywords: Bcl3; Bortezomib; Cutaneous T-cell lymphoma; NFκB; Pro-inflammatory cytokine
references.citation: J Immunol. 2003 Oct 15;171(8):4210-8
references.pmid: 14530344
references.citation: Br J Dermatol. 2013 Mar;168(3):504-12
references.pmid: 23445313
references.citation: Cancer Manag Res. 2012;4:75-89
references.pmid: 22457602
references.citation: Mol Cell Biol. 1994 Jun;14(6):3915-26
references.pmid: 8196632
references.citation: Curr Opin Hematol. 2005 Jul;12(4):273-8
references.pmid: 15928483
references.citation: Clin Lymphoma Myeloma. 2008 Dec;8 Suppl 5:S187-92
references.pmid: 19073526
references.citation: J Immunol. 2013 Sep 1;191(5):2837-46
references.pmid: 23894194
references.citation: Semin Hematol. 2012 Jul;49(3):258-62
references.pmid: 22726549
references.citation: Cell. 1990 Mar 23;60(6):991-7
references.pmid: 2180580
references.citation: Clin Cancer Res. 2013 Jul 15;19(14):3755-63
references.pmid: 23785046
references.citation: J Immunol. 1995 Feb 1;154(3):1491-8
references.pmid: 7822812
references.citation: Clin Cancer Res. 2008 Feb 1;14(3):901-11
references.pmid: 18245554
references.citation: Mod Pathol. 2004 Aug;17(8):911-7
references.pmid: 15105810
references.citation: Semin Oncol. 2007 Dec;34(6 Suppl 5):S21-8
references.pmid: 18086343
references.citation: J Am Acad Dermatol. 2001 Aug;45(2):208-16
references.pmid: 11464181
references.citation: J Clin Invest. 2011 Jan;121(1):265-76
references.pmid: 21157041
references.citation: J Biol Chem. 2014 Jan 31;289(5):2687-700
references.pmid: 24337575
references.citation: Hum Pathol. 2000 Dec;31(12):1482-90
references.pmid: 11150373
references.citation: Expert Rev Hematol. 2011 Oct;4(5):551-62
references.pmid: 21939422
references.citation: J Biol Chem. 2014 Mar 7;289(10):7059-7067
references.pmid: 24459141
references.citation: Curr Treat Options Oncol. 2000 Apr;1(1):43-50
references.pmid: 12057060
references.citation: Genes Chromosomes Cancer. 1997 Sep;20(1):64-72
references.pmid: 9290956
references.citation: J Invest Dermatol. 1991 Nov;97(5):818-23
references.pmid: 1919047
references.citation: Cell Rep. 2012 Oct 25;2(4):824-39
references.pmid: 23063365
references.citation: Genes Dev. 1992 Dec;6(12A):2352-63
references.pmid: 1459457
references.citation: Mediators Inflamm. 2005 Oct 24;2005(5):273-9
references.pmid: 16258194
references.citation: Oncogene. 2006 Oct 30;25(51):6831-43
references.pmid: 17072331
references.citation: Curr Opin Oncol. 2009 Mar;21(2):131-7
references.pmid: 19532014
references.citation: Cell. 1993 Mar 12;72(5):729-39
references.pmid: 8453667
references.citation: Mol Cancer. 2011 Dec 23;10:152
references.pmid: 22195643
references.citation: J Dermatol. 2014 Jan;41(1):11-8
references.pmid: 24438139
references.citation: Eur J Haematol. 2009 Jun;82(6):440-9
references.pmid: 19220424
references.citation: Science. 2007 Aug 3;317(5838):675-8
references.pmid: 17673665
references.citation: Leukemia. 2012 Mar;26(3):424-32
references.pmid: 21904385
references.citation: J Clin Immunol. 2009 Mar;29(2):210-4
references.pmid: 18763027
references.citation: J Hematol Oncol. 2012 May 17;5:24
references.pmid: 22594538
references.citation: J Biol Chem. 2001 Aug 24;276(34):32080-93
references.pmid: 11387332
references.citation: Cancer Invest. 2004;22(2):304-11
references.pmid: 15199612
references.citation: Nature. 1992 Aug 13;358(6387):597-9
references.pmid: 1501714
references.citation: J Virol. 2001 Jul;75(13):6209-11
references.pmid: 11390624
references.citation: Cancer Biol Ther. 2011 Dec 15;12(12):1019-22
references.pmid: 22236880
references.citation: J Immunol. 2014 Mar 15;192(6):2913-9
references.pmid: 24523507
references.citation: Br J Haematol. 2011 Oct;155(2):150-66
references.pmid: 21883142
references.citation: Cancer Res. 1999 Jun 1;59(11):2615-22
references.pmid: 10363983
references.citation: J Virol. 2005 Dec;79(24):15302-13
references.pmid: 16306601
references.citation: J Clin Invest. 2005 Apr;115(4):798-812
references.pmid: 15841167
references.citation: Mol Cancer Res. 2011 Feb;9(2):183-94
references.pmid: 21224428
references.citation: Am J Hematol. 2011 Nov;86(11):928-48
references.pmid: 21990092
references.citation: Blood. 2005 Dec 15;106(13):4287-93
references.pmid: 16123212
references.citation: Cancer Res. 2013 Jan 15;73(2):745-55
references.pmid: 23149915
references.citation: Blood. 2006 Mar 15;107(6):2354-63
references.pmid: 16219794
references.citation: Mol Cell Biol. 1993 Jun;13(6):3557-66
references.pmid: 8497270
references.citation: Leukemia. 2009 Nov;23(11):1964-79
references.pmid: 19741722
references.citation: Blood. 2005 Feb 15;105(4):1640-7
references.pmid: 15514008
references.citation: Blood. 2006 Jul 1;108(1):401-2; author reply 402-3
references.pmid: 16790585
references.citation: Nucleic Acids Res. 1998 Jan 1;26(1):362-7
references.pmid: 9399875
references.citation: Mol Cell Biol. 2009 Aug;29(15):4091-102
references.pmid: 19451226
references.citation: J Clin Oncol. 2007 Sep 20;25(27):4293-7
references.pmid: 17709797
references.citation: Cancer Res. 2009 Mar 15;69(6):2365-74
references.pmid: 19258503
references.citation: Arch Biochem Biophys. 2008 Jul 15;475(2):156-63
references.pmid: 18468507
references.citation: Clin Cancer Res. 2008 Feb 1;14(3):646-53
references.pmid: 18245523
references.citation: Am J Cancer Res. 2013 Nov 01;3(5):433-45
references.pmid: 24224122
references.citation: Lymphokine Cytokine Res. 1994 Feb;13(1):21-7
references.pmid: 8186321
references.citation: Eur J Haematol. 2009 May;82(5):354-63
references.pmid: 19191868
references.citation: J Biol Chem. 1999 Oct 1;274(40):28491-6
references.pmid: 10497212
references.citation: J Virol. 2008 Dec;82(23):11939-47
references.pmid: 18815299
references.citation: Blood. 2013 Aug 8;122(6):943-50
references.pmid: 23801634
references.citation: J Invest Dermatol. 2011 Jun;131(6):1331-8
references.pmid: 21346774